1Velez G, Roy CE, Whiptcup SM, et al. High-dose intravitreal ganciclovir and foscarnet for cyto-megalovirus retinits[J]. Am J Ophthalmol,2001,131(3) :396 - 397
2Frenkel LM, Capparelli EV, Dankner WM, et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects, the pediatric AIDS chinical trial group [J ]. J Infect Dis, 2000, 182 ( 6 ):1016 - 1024
3Mouly S, Aymard G, Diquet B, et al. Oral ganciclovir systemic exposure is enhanced in HIV-infected patients with diarrhea and weight loss[J].J Acquir Immune Defic Syndr,2000,24(4) :344 - 351
4Dubrenil-Lemaire ML,Gori A, Vittecoq D, et al. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for Cytomegalovirus infection:a randomised, placebo-controlled trial in AIDS patients[J ]. Eur J Haematol, 2000,65 (5): 337 - 343
5Croxtall J D. Ganciclovir Ophthalmic Gel 0.15% in acute herpetic keratitis[J]. Drugs, 2011,71 (5): 603.
6Kisore K, Jain S, Zarbin M A. Intravitreal ganciclovir and dexam- ethasone as adjunctive therapy in the management of acute retinal necrosis caused by varicella zoster virus[J]. Ophthalmic Surg Lasers Imaging, 2011, 42:e87.
